Mark McKenna, Mirador Therapeutics CEO

For­mer Prometheus ex­ecs raise $400M for pre­ci­sion im­munol­o­gy start­up: 'The band is back to­geth­er'

Af­ter sell­ing his last com­pa­ny to Mer­ck for $10.8 bil­lion in June, Mark McKen­na couldn’t shake the feel­ing that he’d left the job un­fin­ished.

On Thurs­day, his new start­up Mi­rador Ther­a­peu­tics launched with a mas­sive $400 mil­lion Se­ries A, by far the biggest sin­gle pri­vate fund­ing round of the year in biotech. Led by ARCH Ven­ture Part­ners, more than a dozen oth­er in­vestors chipped in, in­clud­ing Or­biMed, Fair­mount, and Sanofi Ven­tures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.